|
Before joining Antigenics in 2005, Kerry A. Wentworth served as senior director of regulatory affairs at Genelabs Technologies, where she was responsible for the business’ regulatory and quality functions. There she focusing on the late-stage clinical development and subsequent US and European commercial application filings for the company’s lead product Prestara, a treatment for systemic lupus erythrematosus. Prior to Genelabs, Ms. Wentworth held various positions in regulatory affairs at Shaman Pharmaceuticals and at Genzyme Corporation. With more than 12 years of regulatory experience, Ms. Wentworth has considerable expertise in the development, global licensing and post-marketing activities associated with drug and biological products. Ms. Wentworth received a BS in pre-veterinary medicine from the University of New Hampshire. | 